We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pevonedistat is currently in phase 3 studies as a first-line treatment for patients with HR-MDS and higher-risk chronic myelomonocytic leukemia. Read More